Endocyte, Inc. is expected to report first-quarter 2018 results on May 9 after the market closes.
Endocyte logged a negative earnings surprise of 12.50% in the last reported quarter. The company has a mixed earnings surprise record, having surpassed the Zacks Consensus Estimate in two and missing in the other two of the trailing four quarters. Overall, the company delivered an average negative surprise of 1.66%.
Endocyte’s shares have rallied 158.9% year to date, as against the industry’s slip of 3%.
Let's see how things are shaping up for this quarter.
Factors in Play
With no approved product in its portfolio at the moment, investor focus during the Q1 conference will be on updates on Endocyte’s key pipeline candidates EC1169 and EC2629. Endocyte filed an investigational new drug application with the FDA for EC2629 in August 2017 and is planning to initiate a phase I study in patients selected as positive for the folate receptor in cancers where tumor associated macrophages are known to be prevalent in the tumor micro-environment.
Currently, the company is evaluating EC1169 in a phase I study for metastatic castration-resistant prostate cancer in taxane-exposed patients. Patients are being scanned with its companion imaging agent, EC0652, to identify the presence of prostate-specific membrane antigen.
Earnings Whispers
Our proven model does not show an earnings beat for Endocyte this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Endocyte’s has an Earnings ESP of -4.89% as the Most Accurate estimate stands at a loss of 20 cents while the Zacks Consensus Estimate is pegged at a loss of 19 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Endocyte's carries a Zacks Rank #2 which increases the predictive power of ESP. However, we need to have a positive ESP to be confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Keryx Biopharmaceuticals, Inc. has an Earnings ESP of +11.69% and currently carries a Zacks Rank #3. The company is scheduled to release first-quarter results on May 10.
BioDelivery Sciences International, Inc. has an Earnings ESP of +8.70% and currently carries a Zacks Rank #3. The company is scheduled release first-quarter results on May 10.
Paratek Pharmaceuticals, Inc. has an Earnings ESP of +7.31% and currently carries a Zacks Rank #3. The company is scheduled to release first-quarter report on May 9.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Image: Bigstock
What's in Store for Endocyte (ECYT) This Earnings Season?
Endocyte, Inc. is expected to report first-quarter 2018 results on May 9 after the market closes.
Endocyte logged a negative earnings surprise of 12.50% in the last reported quarter. The company has a mixed earnings surprise record, having surpassed the Zacks Consensus Estimate in two and missing in the other two of the trailing four quarters. Overall, the company delivered an average negative surprise of 1.66%.
Endocyte’s shares have rallied 158.9% year to date, as against the industry’s slip of 3%.
Let's see how things are shaping up for this quarter.
Factors in Play
With no approved product in its portfolio at the moment, investor focus during the Q1 conference will be on updates on Endocyte’s key pipeline candidates EC1169 and EC2629. Endocyte filed an investigational new drug application with the FDA for EC2629 in August 2017 and is planning to initiate a phase I study in patients selected as positive for the folate receptor in cancers where tumor associated macrophages are known to be prevalent in the tumor micro-environment.
Currently, the company is evaluating EC1169 in a phase I study for metastatic castration-resistant prostate cancer in taxane-exposed patients. Patients are being scanned with its companion imaging agent, EC0652, to identify the presence of prostate-specific membrane antigen.
Earnings Whispers
Our proven model does not show an earnings beat for Endocyte this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Endocyte’s has an Earnings ESP of -4.89% as the Most Accurate estimate stands at a loss of 20 cents while the Zacks Consensus Estimate is pegged at a loss of 19 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Endocyte's carries a Zacks Rank #2 which increases the predictive power of ESP. However, we need to have a positive ESP to be confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Keryx Biopharmaceuticals, Inc. has an Earnings ESP of +11.69% and currently carries a Zacks Rank #3. The company is scheduled to release first-quarter results on May 10.
BioDelivery Sciences International, Inc. has an Earnings ESP of +8.70% and currently carries a Zacks Rank #3. The company is scheduled release first-quarter results on May 10.
Paratek Pharmaceuticals, Inc. has an Earnings ESP of +7.31% and currently carries a Zacks Rank #3. The company is scheduled to release first-quarter report on May 9.
Endocyte, Inc. Price, Consensus and EPS Surprise
Endocyte, Inc. Price, Consensus and EPS Surprise | Endocyte, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>